If you want a platform built from the ground up around GLP-1 weight loss, with access to both semaglutide and tirzepatide, brand-name options when needed, and provider oversight from clinicians who work exclusively in this space, TrimRx is the more focused option
To order a refill, log in to your account and go to Refill Prescriptions under Prescriptions in the main menu
The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
Si tiene alguna pregunta, puede llamarnos al 949-407-8904 (PST de 8 am a 5 pm)